Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release

NCT05287906 · View on ClinicalTrials.gov ↗

Study Summary

The objectives of this trial are to assess the effects of steviol glycoside alone or in combination with a glycemic carbohydrate on blood glucose and endocrine and gut hormone secretion vs. water and glucose in individuals with normal weight, overweight and type 2 diabetes mellitus (T2DM).

Interventions

  • OTHER Water
  • OTHER Glucose
  • OTHER Steviol Glycosides
  • OTHER Steviol Glycosides plus glucose
  • OTHER Rebaudioside A

Study Locations (3)

Florida

  • Excellence Medical and Research — Miami Gardens
  • Advanced Research for Health Improvement — Naples

Illinois

  • Great Lakes Clinical Trials — Chicago

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2022-04-15
Est. Completion 2024-06-05
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05287906

The ClinicalTrials.gov registry entry for NCT05287906 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Midwest Center for Metabolic and Cardiovascular Research, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 5 interventions — of which Water is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05287906 reports 3 study locations spanning 2 distinct geographic areas — top geographies include Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05287906 about?

NCT05287906 is a clinical study titled "A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release". The objectives of this trial are to assess the effects of steviol glycoside alone or in combination with a glycemic carbohydrate on blood glucose and endocrine and gut hormone secretion vs. water and glucose in individuals with normal weight, overweight and type 2 diabetes mellitus (T2DM).

What is the current status of trial NCT05287906?

This trial is currently completed. It is a NA study. The enrollment target is 69 participants. The study started on 2022-04-15. Estimated completion is 2024-06-05.

What conditions does trial NCT05287906 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Overweight and Obesity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05287906?

The interventions under investigation include: Water (OTHER), Glucose (OTHER), Steviol Glycosides (OTHER), Steviol Glycosides plus glucose (OTHER), Rebaudioside A (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05287906?

This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05287906 being conducted?

This trial has 3 study locations across Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial